1. bookVolume 60 (2022): Edizione 4 (December 2022)
Dettagli della rivista
License
Formato
Rivista
eISSN
2501-062X
Prima pubblicazione
30 Mar 2015
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese
Accesso libero

Association between serum midkine levels and tumor size in Indonesian hepatocellular carcinoma patients: a cross-sectional study

Pubblicato online: 23 Nov 2022
Volume & Edizione: Volume 60 (2022) - Edizione 4 (December 2022)
Pagine: 229 - 234
Dettagli della rivista
License
Formato
Rivista
eISSN
2501-062X
Prima pubblicazione
30 Mar 2015
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese

1. CHEN LT., MARTINELLI E., CHENG AL., PENTHEROUDAKIS G., QIN S., BHATTACHARYYA GS., et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOSESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31(3):334–351.10.1016/j.annonc.2019.12.00132067677 Search in Google Scholar

2. HASAN I., SULAIMAN AS., GANI RA., LESMANA CR. Risk factors for hepatocellular carcinoma and its mortality rate: a multicenter study in Indonesia. Arch Cancer Res. 2019;7(1):2. Search in Google Scholar

3. LOHO IM., SIREGAR L., WASPODO AS., HASAN I. Current practice of hepatocellular carcinoma surveillance. Acta Med Indones. 2018;50(4):353–360. Search in Google Scholar

4. SHU H., LI W., SHANG S., QIN X., ZHANG S., LIU Y. Diagnosis of AFP-negative early-stage hepatocellular carcinoma using Fuc-PON1. Discov Med. 2017;23(126):163–168. Search in Google Scholar

5. PAUL SB., GULATI MS., SREENIVAS V., MADAN K., GUPTA AK., MUKHOPADHYAY S., et al. Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha- fetoprotein. J Oncol. 2007;72(suppl 1):117–123.10.1159/00011171718087192 Search in Google Scholar

6. YANG JD. Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. Clin Mol Hepatol. 2019;25(4): 335–34310.3350/cmh.2019.0010693312330924328 Search in Google Scholar

7. DUAN J., WU Y., LIU J., ZHANG J., FU Z., FENG T., et al. Genetic biomarkers for hepatocellular carcinoma in the era of precision medicine. J Hepatocell Carcinoma. 2019;6:151–166.10.2147/JHC.S224849680578731696097 Search in Google Scholar

8. OCKER M. Biomarkers for hepatocellular carcinoma: what’s new on the horizon? World J Gastroenterol. 2018;24(35):3974–3979.10.3748/wjg.v24.i35.3974614842430254402 Search in Google Scholar

9. HODEIB H., ELSHORA O., SELIM A., SABRY NM., ELASHRY HM. Serum midkine and osteopontin levels as diagnostic biomarkers of hepatocellular carcinoma. Electron Physician. 2017;9(1):3492–3498.10.19082/3492530848628243398 Search in Google Scholar

10. WANG P., MAO YM., ZHAO CN., WANG JB., LI XM., YE DQ., et al. Association of midkine and pleiotrophin gene polymorphisms with systemic lupus erythematosus susceptibility in Chinese Han population. Front Immunol. 2020;11:110.10.3389/fimmu.2020.00110704679432153561 Search in Google Scholar

11. EI-EDEL RH., TAWFIK GA., NORELDIN RI., EL-JAKY MA., EISAA DA. Evaluation of serum midkine as a novel marker in hepatocellular carcinomas. Menoufia Med J. 2018;31(3):1094. Search in Google Scholar

12. PARKIN DM., BRAY F., FERLAY J., PISANI P. Global cancer statistics, 2002. Ca-Cancer J Clin. 2005;55(2):74–108.10.3322/canjclin.55.2.7415761078 Search in Google Scholar

13. KINOSHITA A., ONODA H., FUSHIYA N., KOIKE K., NISHINO H., TAJIRI H. Staging systems for hepatocellular carcinoma: current status and future perspectives. World J Hepatol. 2015;7(3): 406–424.10.4254/wjh.v7.i3.406438116625848467 Search in Google Scholar

14. RICHANI M., KOLLY P., KNOEPFLI M., HERRMANN E., ZWEIFEL M., TENGG-KOBLIGK HV., et al. Treatment allocation in hepatocellular carcinoma: assessment of the BCLC algorithm. Ann Hepatol. 2016;15(1):82–90.10.5604/16652681.118423326626644 Search in Google Scholar

15. MARRERO JA., KULIK LM., SIRLIN CB., ZHU AX., FINN RS., ABECASSIS MM., et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750.10.1002/hep.2991329624699 Search in Google Scholar

16. TELLAPURI S., SUTPHIN PD., BEG MS., SINGAL AG., KALVA SP. Staging systems of hepatocellular carcinoma: a review. Indian J Gastroenterol. 2018;37(6):481–491.10.1007/s12664-018-0915-030593649 Search in Google Scholar

17. DOYLE A., SHERMAN M. Liver biopsy for hepatocelullar carcinoma (HCC): should this be a routine? Curr Hepatol Rep. 2017;16:46–50. Search in Google Scholar

18. HNASKO R. ELISA: Methods and protocols. USA; New York: Humana Press, 2019. Search in Google Scholar

19. WORLD HEALTH ORGANIZATION. World cancer report 2014. http://www.who.int// (accessed 23 May 2020) Search in Google Scholar

20. BALOGH J., VICTOR III D., ASHAM EH., BURROUGHS SG., BOKTOUR M., SAHARIA A., et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3: 41–53.10.2147/JHC.S61146506356127785449 Search in Google Scholar

21. MANIERI E., HERRERA-MELLE L., MORA A., TOMÁS-LOBA A., LEIVA-VEGA L., FERNÁNDEZ DI., et al. Adiponectin accounts for gender differences in hepatocellular carcinoma incidence. J Exp Med. 2019;216(5):1108–1119.10.1084/jem.20181288650421530944152 Search in Google Scholar

22. SAXENA NK., FU PP., NAGALINGAM A., WANG J., HANDY J., COHEN C., et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. J Gastroenterol. 2010;139(5):1762–1773. Search in Google Scholar

23. TANGKIJVANICH P., MAHACHAI V., SUWANGOOL P., POOVORAWAN Y. Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma. World J Gastroenterol. 2004;10(11): 1547–1550.10.3748/wjg.v10.i11.1547457275115162522 Search in Google Scholar

24. EL-SERAG HB., RUDOLPH KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. J Gastroenterol. 2007;132:2557–2576.10.1053/j.gastro.2007.04.06117570226 Search in Google Scholar

25. MAZZAFERRO V., REGALIA E., DOCI R., ANDREOLA S., PULVIRENTI A., BOZZETTI F., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–700.10.1056/NEJM1996031433411048594428 Search in Google Scholar

26. TAKAYAMA T., MAKUUCHI M., KOJIRO M., LAUWERS GY., ADAMS RB., WILSON SR., et al. Early hepatocellular carcinoma: pathology, imaging, and therapy. Ann Surg Oncol. 2008;15:972–978.10.1245/s10434-007-9685-018236118 Search in Google Scholar

27. KO YS., BAE JH., SINN DH., GWAK GY., KANG W., PAIK YH., et al. The clinical significance of serum alpha-fetoprotein in diagnosing hepatocellular carcinoma in a health screening population. Korean J Gastroenterol. 2017;69(4):232–238.10.4166/kjg.2017.69.4.23228449425 Search in Google Scholar

28. TZARTZEVA K., OBI J., RICH NE., PARIKH ND., MARRERO JA., YOPP A., et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. J Gastroenterol. 2018;154(6):1706–1718.10.1053/j.gastro.2018.01.064592781829425931 Search in Google Scholar

29. JING X., CUI X., LIANG H., HAO C., HAN C. Diagnostic accuracy of ELISA for detecting serum midkine in cancer patients. PLoS One. 2017;12(7): e0180511.10.1371/journal.pone.0180511550156028686647 Search in Google Scholar

30. ZHANG BH., LI B., KONG LX., YAN LN., YANG JY. Diagnostic accuracy of midkine on hepatocellular carcinoma: A meta-analysis. PLoS One. 2019; 14(10): e0223514.10.1371/journal.pone.0223514678658531600291 Search in Google Scholar

31. VONGSUVANH R., VAN DER POORTEN D., ISELI T., STRASSER SI., MCCAUGHAN GW., GEORGE J. midkine increases diagnostic yield in AFP negative and NASH-related hepatocellular carcinoma. PLoS One. 2016;11(5): e0155800.10.1371/journal.pone.0155800487879327219517 Search in Google Scholar

32. SHAHEEN KY., ABDEL-MAGEED AI., SAFWAT E., ALBREEDY AM. The value of serum midkine level in diagnosis of hepatocellular carcinoma. Int J Hepatol. 2015; 2015:146389. Search in Google Scholar

33. NAULT J-C. Midkine as a new diagnostic tool in hepatocellular carcinoma. Transl Gastrointest Cancer. 2014;3(2):100–102. Search in Google Scholar

34. ZHANG BH., LI B., KONG LX., YAN LN., YANG JY. Diagnostic accuracy of midkine on hepatocellular carcinoma: A meta-analysis. PLoS One. 2019; 14(10):e0223514.10.1371/journal.pone.0223514 Search in Google Scholar

35. LU Q., CAO H., LV C., WANG X., CAO S. Comparison of diagnostic accuracy of midkine and AFP for detecting hepatocellular carcinoma: A systematic review and meta-analysis. Biosci Rep. 2020;40(3):BSR20192424.10.1042/BSR20192424708732632039435 Search in Google Scholar

36. ZHAO ZQ., YANG S., LU HS. Expression of midkine and vascular endothelial growth factor in gastric cancer and the association of high levels with poor prognosis and survival. Mol Med Rep. 2012;5(2):415–419. Search in Google Scholar

37. ZHU WW., GUO JJ., GUO L., JIA HL., ZHU M., ZHANG JB., et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res. 2013;19(14):3944–3954.10.1158/1078-0432.CCR-12-3363631449123719264 Search in Google Scholar

38. SHIMADA H., NABEYA Y., TAGAWA M., OKAZUMI SI., MATSUBARA H., KADOMATSU K., et al. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci. 2003;94(7):628–632.10.1111/j.1349-7006.2003.tb01494.x12841873 Search in Google Scholar

Articoli consigliati da Trend MD

Pianifica la tua conferenza remota con Sciendo